BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.68% | 502.92% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.68% | 502.92% | -- | -- | -- |
| Cost of Revenue | 52.36% | 150.89% | -- | -- | -- |
| Gross Profit | 122.77% | 1,675.90% | -- | -- | -- |
| SG&A Expenses | -32.80% | -6.02% | 22.13% | 78.52% | 126.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.82% | 0.63% | 26.08% | 51.44% | 58.49% |
| Operating Income | 57.08% | 55.45% | 29.55% | -1.66% | -21.99% |
| Income Before Tax | 93.09% | 84.79% | 62.03% | 30.42% | -52.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.09% | 84.79% | 62.03% | 30.42% | -52.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.09% | 84.79% | 62.03% | 30.42% | -52.71% |
| EBIT | 57.08% | 55.45% | 29.55% | -1.66% | -21.99% |
| EBITDA | 62.16% | 62.32% | 35.37% | 2.62% | -18.59% |
| EPS Basic | 90.94% | 88.17% | 68.25% | 37.78% | -30.26% |
| Normalized Basic EPS | 92.14% | 88.83% | 79.44% | 50.49% | -14.75% |
| EPS Diluted | 90.94% | 88.17% | 68.25% | 37.78% | -30.26% |
| Normalized Diluted EPS | 92.14% | 88.83% | 79.44% | 50.49% | -14.75% |
| Average Basic Shares Outstanding | 47.44% | 24.35% | 23.32% | 22.23% | 21.60% |
| Average Diluted Shares Outstanding | 47.44% | 24.35% | 23.32% | 22.23% | 21.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |